Harvard Medical School investigators at Massachusetts General Hospital have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases and their complications.
In a paper published in the American Journal of Hematology, the research team reported finding that higher levels of a measure routinely taken as part of the complete blood count is caused by reduced clearance of aging cells from the bloodstream.
Hundreds of studies since 2007 have found that elevations in the extent of variation in the size of red blood cells predicted the development, progression and risk of death from many conditions, such as cancer or cardiovascular disease. The measure is called called RDW, short for red blood cell distribution width.
“It appears that the human body slightly slows down the production and destruction of red blood cells in just about every major disease,” said John Higgins, HMS assistant professor of systems biology at Mass General and senior author of the paper. “If we can accurately measure the production or destruction rates, we might be able to identify many of these diseases in their earlier stages, when they are most treatable. Existing measures of the production rate are far too imprecise to detect these subtle changes, but this paper shows how the destruction rate can be estimated using existing blood count data and a mathematical model.”
Healthy adults generate red blood cells at a rate of more than 2 million per second. The cells circulate in the bloodstream for 100 to 120 days, during which their size decreases by around 30 percent. Aged red blood cells are then cleared at about the same rate of 2 million per second.
Prior to the reports associating an elevated RDW with increased risk for many diseases, that measure had been used only to help distinguish between different forms of anemia. In their effort to understand the correlation between RDW and disease prognosis, the Mass General team analyzed raw data from more than 60,000 randomly selected blood samples from the hospital’s clinical laboratories. Using a mathematical model developed by Higgins and a colleague, they replicated how red blood cell populations behave differently in health and in disease.
Using this model to measure the extent to which red blood cells in different phases of their life cycle contribute to increased RDW, they found that the variance in size was strongly determined by mild increases in the numbers of the smallest and oldest cells. Because the most important mechanism controlling the number of the oldest cells is the rate at which they are cleared from the blood stream, the research team made the following predictions, which were validated by applying their model to clinical data from the Mass General blood samples and to data from several published studies:
- Increased RDW was associated with delayed red blood cell clearance.
- Increased RDW was associated with increased average age of red blood cells.
- Delayed red blood cell clearance was as strongly associated with overall risk of death as was increased RDW.
- Delayed red blood cell clearance was associated with the presence of early signs of hidden diseases associated with increased RDW.
- Patients with delayed red blood cell clearance had a greater risk of developing signs of those diseases in the future than did those with a typical clearance rate.
- In healthy patients the rate of red blood cell clearance varied less than did any other traditional blood-count characteristic.
Higgins noted that there are many potential clinical applications of these findings, which need to be validated by future studies.
“Finding a reduced clearance rate in an apparently healthy person would likely mean that an underlying disease process was developing—such as the early stages of iron deficiency, kidney disease, colon cancer or congestive heart failure—and would warrant further diagnostic evaluation,” Higgins said. “Based on this analysis of routine blood tests, a primary care physician could immediately consider appropriate follow-up diagnostic testing, instead of waiting for other signs and symptoms to appear as the condition progresses.”
In a patient with established disease, Higgins added, a reduced clearance rate could mean progression of disease or treatment failure. Imminent complications could be avoided or reduced by adjusting treatment right away or at least by more frequent monitoring.
“In addition to confirming our findings in prospective studies that would follow a group of patients over time, we hope to identify the diseases for which an early warning provided by delayed clearance would lead to the most significant improvements in patient outcomes,” Higgins said. “We’d also like to understand more about the processes controlling red blood cell clearance and are actively developing similar models for populations of white blood cells and platelets.”
The study was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K08DK083242, National Institutes of Health Director’s New Innovator Award DP2DK098087 and Abbott Hematology.
Adapted from a Mass General news release.
Stay informed via email on the latest news, research, and
media from Harvard Medical School.